Find Reports
Select Report Type
Reimbursement Review
Displaying 101 - 125 of 1422
Please scroll or swipe to the right to view the full content.
| Title | Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
|---|---|---|---|---|---|---|---|---|---|
| niraparib abiraterone acetate | Akeega | niraparib abiraterone acetate | Metastatic castration-resistant prostate cancer (mCRPC) | Reimburse with clinical criteria and/or conditions | Complete | PC0326-000 | |||
| sacituzumab govitecan | Trodelvy | sacituzumab govitecan | HR+, HER2− advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0323-000 | |||
| olaparib | Lynparza | olaparib | Metastatic castration-resistant prostate cancer (mCRPC) | Reimburse with clinical criteria and/or conditions | Complete | PC0319-000 | |||
| vutrisiran | Amvuttra | vutrisiran | Hereditary transthyretin mediated amyloidosis (hATTR amyloidosis) | Reimburse with clinical criteria and/or conditions | Complete | SR0801-000 | |||
| evinacumab | Evkeeza | evinacumab | Homozygous familial hypercholesterolemia (HoFH) | Reimburse with clinical criteria and/or conditions | Complete | SR0778-000 | |||
| eltrombopag | N/A | eltrombopag | Severe Aplastic Anemia (SAA) | Reimburse with clinical criteria and/or conditions | Complete | SX0777-000 | |||
| ibrutinib | Imbruvica | ibrutinib | Waldenström’s Macroglobulinemia | Reimburse with clinical criteria and/or conditions | Complete | PC0328-000 | |||
| calaspargase pegol | Asparlas | calaspargase pegol | Acute lymphoblastic leukemia (ALL) | Reimburse with clinical criteria and/or conditions | Complete | PC0321-000 | |||
| bevacizumab and lomustine | N/A | bevacizumab and lomustine | Recurrent glioblastoma multiform | Reimburse with clinical criteria and/or conditions | Complete | PX0318-000 | |||
| polatuzumab vedotin | Polivy | polatuzumab vedotin | Large B-cell lymphoma | Do not reimburse | Complete | PC0313-000 | |||
| upadacitinib | Rinvoq | upadacitinib | Crohns disease | Reimburse with clinical criteria and/or conditions | Complete | SR0775-000 | |||
| efgartigimod alfa | Vyvgart | efgartigimod alfa | Generalized myasthenia gravis (gMG) | Reimburse with clinical criteria and/or conditions | Complete | SR0782-000 | |||
| andexanet alfa | Ondexxya | andexanet alfa | Reversal of FXa inhibitor anticoagulant effects | Do not reimburse | Complete | ST0772-000 | |||
| elexacaftor/tezacaftor/ivacaft... | Trikafta | elexacaftor/tezacaftor/ivacaftor and ivacaftor | Cystic fibrosis, F508del CFTR mutation, 2 years and older | Reimburse with clinical criteria and/or conditions | Complete | SR0776-000 | |||
| somapacitan | Sogroya | somapacitan | Growth Hormone Deficiency (GHD) | Reimburse with clinical criteria and/or conditions | Complete | SR0779-000 | |||
| mirikizumab | Omvoh | mirikizumab | Ulcerative colitis | Reimburse with clinical criteria and/or conditions | Complete | SR0773-000 | |||
| cabozantinib | Cabometyx | cabozantinib | Advanced or metastatic renal cell carcinoma | Reimburse with clinical criteria and/or conditions | Complete | PC0312-000 | |||
| durvalumab and tremelimumab | Imfinzi and Imjudo | durvalumab and tremelimumab | unresectable hepatocellular carcinoma | Reimburse with clinical criteria and/or conditions | Complete | PC0308-000 | |||
| rivaroxaban | N/A | rivaroxaban | Venous thromboembolic events (VTE) | Reimburse with clinical criteria and/or conditions | Complete | SX0750-000 - SR0750-000 | |||
| ibrutinib | Imbruvica | ibrutinib | Chronic lymphocytic leukemia (CLL) | Reimburse with clinical criteria and/or conditions | Complete | PC0317-000 | |||
| axicabtagene ciloleucel | Yescarta | axicabtagene ciloleucel | Relapsed or refractory follicular lymphoma | Reimburse with clinical criteria and/or conditions | Complete | PG0314-000 | |||
| setmelanotide | Imcivree | setmelanotide | Bardet-Biedl syndrome | Reimburse with clinical criteria and/or conditions | Complete | SR0769-000 | |||
| dupilumab | Dupixent | dupilumab | Atopic dermatitis, pediatrics | Reimburse with clinical criteria and/or conditions | Complete | SR0774-000 | |||
| nelarabine | Atriance | nelarabine | T-cell acute lymphoblastic leukemia | Reimburse with clinical criteria and/or conditions | Complete | PC0307-000 | |||
| abiraterone, prednisone, docet... | N/A | abiraterone, prednisone, docetaxel | Metastatic castration sensitive prostate cancer (mCSPC) | Reimburse | Complete | PX0298-000 - PC0298-000 |
Health Technology Review
Displaying 101 - 125 of 600
Please scroll or swipe to the right to view the full content.
| Title | Description | Files | Last Updated Sort ascending | Project Sub Line | Status | Project Number |
|---|---|---|---|---|---|---|
| Renal Denervation | Rapid Review | Completed | RC1532-000 | |||
| Long-Term Use of Omalizumab for Chronic Idiopathic Urticaria | Technology Review | Completed | HC0053-000 | |||
| Patterns in Utilization of Long-Acting Inhaled Drugs for the Treatment of Chronic Obstructive Pulmonary Disease | Technology Review | In Progress | HC0086 -000 | |||
| NovoTTF-200A | Optimal Use | Completed | OP0554-000 | |||
| Utilization Analysis of Tofacitinib and Other Drugs Among Individuals With Ulcerative Colitis: Feasibility Analysis | Observational Study | Complete | OS0003-000 | |||
| Reprocessed Single-Use Semicritical and Critical Medical Devices | We sought to identify and summarize literature evaluating the clinical safety of reprocessed single-used medical devices (SUMDs), defined as infections, mortality, or other adverse events, compared with nonreprocessed (new) SUMDs. | Rapid Review | Completed | RC1511-000 | ||
| Aerosol Therapy With Inhalers During Mechanical Ventilation | Rapid Review | Completed | RC1529-000 | |||
| Pan- Canadian Rare Disease Registries | Environmental Scan | Completed | ES0369-000 | |||
| Ketamine for Adults With Substance Use Disorders | To inform decisions about using ketamine for treating SUDs, we sought to identify and summarize the literature comparing the clinical and cost-effectiveness of ketamine with placebo or no treatment, with alternative interventions, or among ketamine administered via different routes for SUDs. | Rapid Review | Completed | RC1523-000 | ||
| Intra-Articular Hyaluronic Acid for Osteoarthritis of the Hip, Shoulder, and Ankle | Rapid Review | Completed | RC1528-000 | |||
| Opioid-Sparing Effects of IV Acetaminophen for Patients Undergoing Surgery | Rapid Review | Completed | RC1530-000 | |||
| Cost-Effectiveness of Respiratory Syncytial Virus Vaccines for Adults | Technology Review | Completed | HE0047 -000 | |||
| Timing of Antibiotic Therapy for Neisseria Gonorrhoeae Infection | Rapid Review | Completed | RC1527-000 | |||
| Clinical and Instrumental Swallowing Assessments for Dysphagia | Rapid Review | Completed | RC1526-000 | |||
| Average Volume of MRI Exams Conducted per Hour Across Canada | Using data from the national Canadian Medical Imaging Inventory 2019 to 2020 survey, we calculated an average of MRI exams performed per hour across Canada | CMII Service | Completed | CM0008-000 | ||
| Biologic Drugs for Severe Asthma | Technology Review | Completed | RE0047-000 | |||
| Buprenorphine Formulations for Opioid Use Disorder | Systematic Review | Completed | RE0051-000 | |||
| The Safety of Niraparib in Ovarian Cancer | To give clinicians and policy-makers a better understanding of the niraparib’s risk profile, researchers conducted an observational study to look at how the safety and tolerability of niraparib in the real world compares with observations from seminal clinical trials. | Observational Study | Active | OS0002-000 | ||
| Ketamine for Adults With Treatment-Resistant Depression or Posttraumatic Stress Disorder: A 2023 Update | We conducted a review of the clinical effectiveness, cost-effectiveness, and evidence-based guidelines on the use of ketamine in adults with TRD or PTSD, to help guide decisions on the use of ketamine for managing these conditions. | Rapid Review | Completed | RC1522-000 | ||
| Endobronchial Valves for the Management of Severe Emphysema | Rapid Review | Completed | RC1524-000 | |||
| Ketorolac for Renal Colic | Rapid Review | Completed | RC1525-000 | |||
| Immune checkpoint inhibitors for mutated non–small cell lung cancer | Observational Study | In Progress | OS0008-000 | |||
| Leucovorin Dosing for Gastrointestinal Cancer | Rapid Review | Completed | RC1518-000 | |||
| Ketamine for Chronic Non-Cancer Pain: A 2023 Update | Summary with Critical Appraisal | Completed | RC1521-000 | |||
| Screening for Colorectal Cancer in Individuals Younger Than 50 Years | Rapid Review with Expert Input | Completed | RD0069-000 |
Horizon Scan
Displaying 101 - 110 of 110
Please scroll or swipe to the right to view the full content.
| Title | Description | Files | Last Updated Sort ascending | Project Sub Line | Status | Project Number |
|---|---|---|---|---|---|---|
| Dementia Villages | Emerging Health Technologies | Completed | EH0071-000 | |||
| Dementia Villages - Position Statement | EH0071-000 | |||||
| Dementia Villages: Innovative Residential Care for People With Dementia | EH0071-000 | |||||
| Health Technology Update — Issue 24 | Health Technology Update | Completed | EN0014-000 | |||
| Esketamine for Treatment-Resistant Depression | EH0075-000 | |||||
| Horizon Scan Roundup — 2018 | ER0007-000 | |||||
| Health Technology Update — Issue 23 | Health Technology Update | Completed | EN0013-000 | |||
| An Overview of Clinical Applications of Artificial Intelligence | Emerging Health Technologies | Completed | EH0070-000 | |||
| Alternating Electric Fields ("Tumour- Treating Fields") for the Treatment of Glioblastoma | Emerging Health Technologies | Completed | EH0060-000 | |||
| Buprenorphine Implant for the Treatment of Opioid Use Disorder | Completed | EH0044-000 |
Projects in Progress
Displaying 26 - 27 of 27
View All Reports
Displaying 101 - 125 of 2132
Please scroll or swipe to the right to view the full content.
| Title | Description | Files | Last Updated Sort ascending | Project Line | Project Sub Line | Status | Project Number |
|---|---|---|---|---|---|---|---|
| Switching Calcitonin Gene–Related Peptide Inhibitors for Migraine Prophylaxis | Health Technology Review | Peer-reviewed Summary with Critical Appraisal | Completed | RD0071-000 | |||
| tarlatamab | Reimbursement Review | Active | PC0351-000 | ||||
| Cladribine and Natalizumab for Relapsing-Remitting Multiple Sclerosis | Reimbursement Review | Streamlined Drug Class Review | Active | TS0004-000 | |||
| cladribine | Reimbursement Review | Complete | SR0546-000 | ||||
| venetoclax | Reimbursement Review | Complete | PC0362-000 | ||||
| Natalizumab | Reimbursement Review | Complete | SR0133-000 | ||||
| Multiple Myeloma | Reimbursement Review | Provisional Funding Algorithm | Active | PH0068-000 | |||
| inebilizumab | Reimbursement Review | Pending | SR0889-000 | ||||
| vanzacaftor, tezacaftor, deutivacaftor | Reimbursement Review | Pending | SR0896-000 | ||||
| Trends in Opioid Prescribing in Canada, 2018-2022 | This study analyzed trends in prescription opioid use for pain and opioid agonist therapy from January 2018 to December 2022 across 6 Canadian provinces. | Health Technology Review | Technology Review | Completed | HC0071-000 | ||
| crovalimab | Reimbursement Review | Active | SR0858-000 | ||||
| 2025 Watch List: Artificial Intelligence | The 2025 Watch List focuses on the use of artificial intelligence technologies in health care and the issues that may arise with the implementation of these technologies. | Horizon Scan | Roundup | Completed | ER0015-000 | ||
| danicopan | Reimbursement Review | Complete | SR0815-000 | ||||
| enfortumab vedotin | Reimbursement Review | Complete | PC0353-000 | ||||
| pembrolizumab | Reimbursement Review | Active | PC0377-000 | ||||
| pembrolizumab | Reimbursement Review | Active | PC0369-000 | ||||
| Planning for the Introduction of New CT Services in Rural and Remote Communities in Canada | We conducted an informal survey among senior medical imaging decision-makers to determine the factors that influence planning for new CT services in rural and remote communities in Canada. | Health Technology Review | CMII Service | Completed | CM0032-000 | ||
| zolbetuximab | Reimbursement Review | Active | PC0338-000 | ||||
| Virtual Remote Imaging Services: CT and MRI Scanning | Health Technology Review | CMII Service | Active | CM0017-000 | |||
| vorasidenib | Reimbursement Review | Pending | PC0407-000 | ||||
| dostarlimab | Reimbursement Review | Active | PC0381-000 | ||||
| momelotinib | Reimbursement Review | Active | PC0355-000 | ||||
| garadacimab | Reimbursement Review | Active | SR0860-000 | ||||
| amivantamab | Reimbursement Review | Active | PC0376-000 | ||||
| Comparative Effectiveness of Real-Time Teleultrasound Versus In-Person Ultrasound | Health Technology Review | CMII Service | Completed | CM0024-000 |